“…As previously described, patients were diagnosed with CML-AP based on the standard definition (i.e., hematologic criteria 4 or clonal evolution); patients with progression of a prior CML-AP diagnosis after achieving a hematologic response were also eligible 4 . Clonal evolution included additional chromosomal abnormalities besides the Ph chromosome (e.g., +8, +19, iso17q) 8 . After 2 years, patients who experienced-specific AEs (e.g., any-grade recurring fluid retention, including pleural and/or pericardial effusion, or any-grade gastrointestinal bleed despite dose reduction by one level) were allowed to switch from BID to QD dosing, but data were analyzed based on the initial randomization arm.…”